24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Blame Diabetes: Rates of 2 Nerve Conditions on the RiseElectronic Messaging Intervention Cuts Cardiovascular Risk in T2DMHealth Tip: Preventing Diabetic Foot SoresEarly Menopause May Be Tied to Type 2 DiabetesMore Than 100 Million Americans Have Diabetes or Prediabetes: CDCNT-proBNP Improves Heart Failure Prediction in T2DMStem Cell Educator Therapy May Help Fight DiabetesResistance Training Improves Microvascular Blood Flow in T2DMNew Diabetes Treatment Teaches Rogue Immune Cells to BehaveIncreased Parental Anxiety With Increased Diabetes RiskIntensive Lifestyle Changes May Up Frailty Fracture Risk in DMExercising Safely With DiabetesHyperbaric Oxygen Therapy Increasingly Being UsedTherapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 PercentT1DM Patients With Active β-Cell Function Differ ImmunologicallyMany People With Type 1 Diabetes Still Make Some InsulinTryptophan May Be Marker for Diabetic NephropathyEstimated Prevalence of Diabetes 10.9 Percent in ChinaReview Spotlights Optimal Care of T2DM + OsteoporosissRAGE Linked to Risk of Incident Diabetic NephropathyDiabetic Ketoacidosis Poses Fetal Risk During/After EventFDA Warns Diabetics Against Use of Secondhand Test StripsRisk of Cardiovascular Events Similar With, Without DiabetesPCSK9 Increased in Females, Youth With Type 1 DiabetesText Messaging Intervention Can Up Glycemic Control in T2DMGood Results for Zone MPC-Based Artificial PancreasBroccoli Extract Shows Promise for Type 2 DiabetesSleep Apnea Linked to Diabetic Retinopathy in Type 2 DiabetesADA: Canagliflozin Tied to Lower Risk of Cardiovascular EventsKey Diabetes Test Gives Higher Blood Sugar Readings in Black PatientsFor Diabetics, Nasal Powder Fixed Severe Low Blood SugarADA: Glucose Self-Monitoring Often Lacks Benefit in T2DMCan Folks With Type 2 Diabetes Forgo the Finger Stick?Sitagliptin Stimulates Distal Tubular Natriuresis in T2DMStudy Confirms Link Between Diabetes Med and Rare But Dangerous ComplicationLower HbA1c Linked to Better Diabetes-Specific HRQoL in YouthHealth Tip: What's My Target Blood Glucose?Comorbid Celiac Disease Common Among Youth With T1DMDiabetic Foot Ulcers, Infections Significantly Up Burden of CareMapping IDs Geographic Access Barriers for Diabetic RetinopathyNormal Meal Tolerance Test Is Practical, Reliable in T2DMNo Link to Cognition in Diabetes Prevention Program StudySuicide by Insulin?Promising Start for National Diabetes Prevention ProgramDiabetes Drug Gets FDA Warning Due to Amputation RiskAngela Bassett Puts the Spotlight on Heart HealthAs Temps Rise, Risk of Pregnancy Complication May TooPharmacist-Involved Collaborative Care Benefits T2DMNever Breastfeeding Linked to Increased Risk of T1DMBioengineered Intraabdominal Endocrine Pancreas Feasible
Links
Related Topics

Medical Disorders

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy


HealthDay News
Updated: Apr 27th 2017

new article illustration

THURSDAY, April 27, 2017 (HealthDay News) -- Three anti-vascular endothelial growth factor (anti-VEGF) treatments are associated with low rates of diabetic retinopathy (DR) worsening, according to a study published online April 27 in JAMA Ophthalmology.

Susan B. Bressler, M.D., from Johns Hopkins University, and colleagues conducted preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME in 650 participants during two years of treatment with aflibercept (2 mg), bevacizumab (1.25 mg), or ranibizumab (0.3 mg).

The researchers found that at one year, among 423 nonproliferative DR (NPDR) eyes, 44 of 141 (31.2 percent) treated with aflibercept, 29 of 131 (22.1 percent) with bevacizumab, and 57of 151 (37.7 percent) with ranibizumab had improvement of DR severity (P = 0.004 for aflibercept versus bevacizumab, P = 0.01 for ranibizumab versus bevacizumab, and P = 0.51 for aflibercept versus ranibizumab). At two years, no treatment group differences were identified. Among the 93 eyes with proliferative DR (PDR) at baseline, one-year improvement rates were 75.9 percent for aflibercept, 31.4 percent for bevacizumab, and 55.2 percent for ranibizumab (P < 0.001 for aflibercept versus bevacizumab, P = 0.09 for ranibizumab versus bevacizumab, and P = 0.02 for aflibercept versus ranibizumab). These rates and group differences were maintained at two years.

"All three anti-VEGF treatments were associated with low rates of DR worsening. These data provide additional outcomes that might be considered when choosing an anti-VEGF agent to treat DME," conclude the authors.

Several authors report financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)